Related Experiment Videos
Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and
Abstract:
Mevinolin is a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase; EC 1.1.1.34), an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. We have been studying the hepatic distribution of reductase with immunofluorescence microscopy and liver ultrastructure with electron microscopy in normal and drug-treated rats. In control animals, only about 20% of the hepatocytes were reductase positive. These cells were localized in the periportal lobular zones. The numbers of positive hepatocytes in animals given mevinolin or cholestyramine (or both) were directly proportional to the activities of the HMG-CoA reductase determined biochemically. This induction of HMG-CoA reductase immunofluorescence was centered periportally. Rats given 0.075% mevinolin alone had a homogeneous distribution of reductase staining in their hepatocyte cytoplasm, whereas a combination of 0.25% mevinolin and 3% cholestyramine caused a 150-fold increase in enzyme activity and induced prominent juxtanuclear immunofluorescent globules of HMG-CoA reductase in all hepatocytes. With electron microscopy, these bodies were composed of tightly packed stacks of smooth endoplasmic reticulum cysternae and aggregates of branched smooth endoplasmic reticulum tubules. Our data suggest that a subpopulation of periportal rat hepatocytes may be uniquely specialized for cholesterol synthesis.
Insights
Mevinolin, a cholesterol synthesis inhibitor, affects 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) distribution in rat liver cells. Studies reveal periportal hepatocytes may specialize in cholesterol production.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Cholesterol biosynthesis is a critical metabolic pathway regulated by 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase).
- HMG-CoA reductase catalyzes the rate-limiting step in cholesterol synthesis.
- Mevinolin is a known potent inhibitor of HMG-CoA reductase.
Purpose of the Study:
- To investigate the hepatic distribution of HMG-CoA reductase in normal and drug-treated rats.
- To examine the effect of mevinolin and cholestyramine on HMG-CoA reductase activity and localization.
- To elucidate the ultrastructural changes in hepatocytes associated with altered HMG-CoA reductase levels.
Main Methods:
- Immunofluorescence microscopy was employed to study the hepatic distribution of HMG-CoA reductase.
- Electron microscopy was utilized to analyze liver ultrastructure.
- Biochemical assays were performed to determine HMG-CoA reductase activity.
Main Results:
- In control rats, HMG-CoA reductase was primarily detected in periportal hepatocytes (approx. 20%).
- Mevinolin and cholestyramine treatments increased HMG-CoA reductase levels, with induction proportional to enzyme activity.
- High-dose combination treatment resulted in homogeneous reductase staining and juxtanuclear globules composed of smooth endoplasmic reticulum, observed via electron microscopy.
Conclusions:
- HMG-CoA reductase induction by mevinolin and cholestyramine is concentrated in periportal hepatocytes.
- Ultrastructural changes, including smooth endoplasmic reticulum proliferation, accompany high HMG-CoA reductase activity.
- A subpopulation of periportal rat hepatocytes exhibits specialization for cholesterol synthesis.